SMA and Morphosys will probably have to leave the MDax in the upcoming review of the index compositions of Deutsche Börse.

According to the data provider LSEG, the respective market capitalizations of the free float of the solar industry supplier and the biotech company are not sufficient for them to remain in the German small cap index.

Morphosys is about to be taken over by the Swiss pharmaceutical group Novartis. SMA shares have lost around 20% since the beginning of the year due to the gloomy outlook for 2024. One possible candidate for promotion to the MDax is TUI. The tourism group returned to the Frankfurt Stock Exchange with its main listing at the beginning of April. DWS, the fund subsidiary of Deutsche Bank, and the commercial vehicle manufacturer Traton also have high hopes.

Next Wednesday, Deutsche Börse will announce any changes to the index composition that will take effect on June 24. No changes are expected in the Dax. The decisive factor for index membership is the market capitalization of the free float. This is based on the last trade-weighted average price of the month preceding the review date. Reuters uses the current average prices and free float ratios provided by the data provider LSEG for the calculations. Index-tracking funds must adjust their portfolios accordingly in the event of changes, which can move share prices.

(Report by Hakan Ersen, edited by Christian Rüttger. If you have any questions, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and the economy) or frankfurt.newsroom@thomsonreuters.com (for companies and markets).)